To receive the Femtech World newsletter, sign up here.
News
Cryostorage facility launches new entity to provide IVF clinics with ‘holistic’ cryostorage solution
Cryo-Logix aims to utilise clinic EMR data to ensure streamlined communication between systems
A US cryostorage facility has launched a new entity specialising in providing IVF clinics with an “end-to-end” cryostorage solution.
ReproTech has announced the launch of Cryo-Logix as a separate entity within the company, with a focus on enabling IVF clinics to provide better care to their patients.
Cryo-Logix claims to utilise clinic EMR data to ensure streamlined communication between systems. According to ReproTech, complimentary transport of specimens to and from IVF clinics will also be available as a service to help ensure there are no interruptions for patients preparing for treatment.
The Cryo-Logix’s team, the company says, will help to alleviate the administrative burdens that many IVF clinics face by taking responsibility for invoicing, collections, patient outreach, logistics and disposition for cryogenic inventory whether it is stored at the IVF clinic tank or at ReproTech.
Brad Senstra, chief executive officer at ReproTech, said: “IVF clinics have been searching for a best-in-class end-to-end cryostorage solution that reduces the risks of storing human tissue on-site at fertility clinics.
“As the undisputed experts in long-term cryogenic storage, we created Cryo-Logix to meet this critical need and to provide peace of mind for clinic staff who wake up every day with the singular goal of helping to ensure that their patients receive the highest levels of care and treatment.”
ReproTech has previously worked with multiple of clinics in the US, including private IVF practices and large university and hospital IVF programmes, providing storage for thousands of human specimens via disaster-proof safe storage rooms that are purpose built for all natural disasters.
The company says it has multi-layer monitoring and redundant proprietary systems in place to protect precious reproductive tissue specimens.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience






